Gilead Sciences | Stammkapital

Aktienkurs
151.44
Täglich Wechseln
0.32 0.21%
Monatlich
17.30%
Jährlich
37.74%
Q1 Prognose
150.18




Stammkapital Veränderung Datum
AbbVie USD 1.77B 1.75B 2025-06
Agios Pharmaceuticals USD 58.45M 169K 2025-12
ALKERMES USD 165.1M 49K 2025-09
Alnylam Pharmaceuticals USD 132.38M 585K 2025-12
Amgen USD 539M 1000K 2025-12
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 192.1M 97K 2025-09
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Coherus Biosciences USD 12K 0 2025-03
Eli Lilly USD 946.83M 354.23M 2025-06
Gilead Sciences USD 1.24B 1000K 2025-12
GlaxoSmithKline GBP 4.08B 49.43M 2025-12
Glaxosmithkline GBP 4.03B 2.68B 2025-09
Incyte USD 198.46M 2.33M 2025-12
J&J USD 2.41B 584K 2025-09
Merck USD 2.49B 15.79M 2025-09
Moderna USD 391M 2M 2025-09
Neurocrine Biosciences USD 100.1M 400K 2025-12
Novartis USD 1.94B 23.4M 2025-06
Pfizer USD 5.69B 1000K 2025-09
PTC Therapeutics USD 81.47M 1.54M 2025-12
Puma Biotechnology USD 5K 0 2024-06
Regeneron Pharmaceuticals USD 105.3M 1.1M 2025-09
Sarepta Therapeutics USD 104.77M 7.06M 2025-09
United Therapeutics USD 42.9M 42.1M 2025-09
Vertex Pharmaceuticals USD 254M 0 2025-12


Gilead Sciences Stammkapital - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Feb 2026.